News & Events
Welcome to the NTx newsroom
Dame Molly Stevens @ ScSB summit
Dr. Stevens, esteemed Oxford professor and scientific advisor and board member for NanoVation Therapeutics UK, will present at the Scandinavian Society for Biomaterials (ScSB) Annual Meeting on April 24th, 2024.
Pieter Cullis inducted into Canadian Medical Hall of Fame
The Canadian Medical Hall of Fame (CMHF) has named NTx co-founder and Board Chair Dr. Pieter Cullis one of its 2024 inductees, recognizing him as an icon of Canadian health leadership.
NTx Pioneers Present @ Castle Delivery Meeting Redux
Pieter Cullis, our Board Chair and co-founder, alongside Jayesh Kulkarni, our Chief Scientific Officer, will take the stage at the Castle Delivery Meeting Redux in Sicily on April 7th.
Pieter Cuillis @ MSKCC Seminar Series
Pieter Cullis is keynote speaker at the MSKCC's Molecular Pharmacology and Chemical Biology Research Seminar Series in New York.
NTx’s Drs. Dominik Witzigmann & Pieter Cullis publish in PNAS
This landmark publication, showcasing work by NTx co-founders Drs Pieter Cullis & Dominik Witzigmann, introduces a revolutionary magnetic separation technique that transforms the way we isolate and analyze the biomolecular corona of lipid nanoparticles.
NTx’s CEO @ RNA Leaders Europe 2024
Our CEO, Dominik Witzigmann, PhD, will be representing NTx at the RNA Leaders Europe 2024 conference in Basel!
NanoVators @ NMIN’s 2024 Research Conference
NTx leaders will be at NMIN's 2024 Research Conference in Vancouver to deliver the Industry & Research keynote presentations.
Pieter Cullis @ Keystone Symposia
Pieter Cullis, NTx co-founder and Board Chair, takes centre stage at the Delivery of Nucleic Acid Therapeutics Meeting (Keystone Symposia) in Banff, Alberta.
NTx Prof. Molly Stevens made a Dame
Scientific Advisor & Board Member (NTx UK) Molly Stevens has been appointed Dame of the Most Excellent Order of the British Empire for her outstanding services to Medicine.
NTx co-founders publish in Science Advances
This publication by NTx co-founders Drs Christian Kastrup, Pieter Cullis, and Eric Jan, highlights groundbreaking cell therapy research that will shape the future of genetic medicines.
NanoVators @ 2023 mRNA Health Conference
At the International mRNA Health Conference in Berlin, NTx folks met with Nobel laureate Katalin Karikó, and our VP of Chemistry, Marco Ciufolini, presented on LNPs for gene therapy.
NanoVators @ ISV Annual Congress
NTx Preclinical Immunology Scientist Jessica Silva presented a poster in the 2023 International Society for Vaccines in Lausanne, Switzerland.
NTx’s Molly Stevens @ Thermis-AP & StemNet
NTx Scientific Advisor & Board Member (UK) Molly Stevens is presenting at Thermis-AP Conference 2023 in Hong Kong and at the StemNet Meeting in Brescia, Italy.
NTx scientist Daniel Kurek presents @ Vancouver RNA Club
NTx is a proud sponsor of the Vancouver RNA Club event next week at which NTx Senior Scientist, Formulation, Daniel Kurek, will present.
NTx well-represented at CLINAM 2023 in Basel
Board Chair Pieter Cullis and CEO Dominik Witzigmann were among the NTx team members participating in the European Foundation for Clinical Nanomedicine (CLINAM) meeting in Basel.
NTx Co-Founder Eric Jan hosts mentoring lunch @ RiboClub Annual Meeting
Eric Jan, NTx Co-founder, hosts a mentoring lunch on Sept 25 as part of the 2023 RiboClub Annual Meeting in Quebec.
Pieter Cullis & Jay Julkarni @ Next-Generation Nanomedicine symposium
We're thrilled to announce that NTx Co-Founder Pieter Cullis will be keynote speaker at the Next-Generation Nanomedicine symposium.
Christian Kastrup presents @ MHSRS
Co-founder Dr. Christian Kastrup is presenting on Aug 15 in the Military Health System Research Symposium.
Pieter Cullis appointed to the Order of British Columbia
NTx Co-Founder Dr. Pieter Cullis has been appointed to the Order of BC, the province's highest honour.
Christian Kastrup presents guest lecture @ BCCHR
NTx co-founder Dr. Christian Kastrup will deliver a guest lecture at BC Children's Hospital Research Institute on August 2nd.
Dr. Pieter Cullis elected a Fellow of the Royal Society
NTx Co-Founder Dr. Pieter Cullis has been elected Fellow of the prestigious UK Royal Society.
Pieter Cullis speaks @ Annual RNATx Conference 2023
NTx Co-founder Pieter Cullis is a keynote speaker (with colleague Katalin Karikó) at the 5th Annual RNATx Conference, 21-23 June 2023 in Worcester, MA.
Kevin An @ CBS 2023 Annual Meeting in Halifax
NTx team member Kevin An will be talking about NanoVation's lcLNP at the CBS Annual Meeting in Halifax this Thursday afternoon.
Arpan Desai @ Cambridge Wide Open Day 2023
Arpan Desai will present an “Introduction to mRNA Based Therapeutics for COVID and Beyond” as part of Cambridge Wide Open Day on June 14.
Molly Stevens & Arpan Desai @ Nanomed Europe 23
Event
Next week at Nanomed Europe 23, NTx will be well represented. Molly Stevens, NTx UK Board Member and ...
CSO Jayesh Kulkarni @ HLI Seminar Series at UBC
NTx CSO Jayesh Kulkarni will be showing off his LNP expertise in the Centre for Heart Lung Innovation (HLI) Seminar Series on June 2 at UBC.
Kevin An @ ASGCT 26th Annual Meeting
Catch the May 17 presentation by NTx Formulation Scientist Kevin An at the ASGCT 26th Annual Meeting.
Pieter Cullis honoured as the 19th D. Harold Copp Lecturer
NTx Co-Founder Dr. Pieter Cullis was honoured as the 19th D. Harold Copp Lecturer on 5 May.
Pieter Cullis speaks @ Gairdner event
NTx Co-Founder Dr. Pieter Cullis, delivers a keynote talk & participates in a panel at a Gairdner Award event on May 9.
CSO Jayesh Kulkarni @ ISI 2023 in Brazil
NTx CSO Dr. Jayesh Kulkarni will discuss next-gen LNPs on a panel at the Institute of Technology in Immunobiology (ISI) 2023 in Brazil.
NTx @ RNA Leaders Europe Congress 2023
We'll be there! NTx is a proud co-sponsor of RNA Leaders Europe Congress (Basel, 15-16 March).
Particle Works partners with NTx UK for LNP development
Particle Works is collaborating with NTx UK to reduce the time and costs associated with the screening of novel LNP formulations for use in nucleic acid delivery applications.
NTx CSO Dr Jayesh Kulkarni will be talking at the LNP Immunogenicity & Toxicity Summit in Boston on Dec 8.
CEO Dominik Witzigmann @ BioFIT 2022
NTx CEO Dominik Witzigmann will be part of the panel discussion focused on the potential of mRNA technology as a therapeutic platform at the BioFIT Event 2022 Conference in Strasbourg.
CBO Don Enns @ Blakes Breakfast Series
Our Chief Business Officer Don Enns is an invited speaker to the Blakes Breakfast Series, on Wednesday 16 Nov.
Innovate BC supports NanoVation project to improve mRNA stability and production for vaccines
A project being led by NTx and Dr. Eric Jan of UBC has been awarded the maximum funding allotment available through BC Innovate's Ignite program.
Co-Founder Dr. Pieter Cullis wins 2022 Bloom Burton Award
The Board Chair and Co-Founder of NTx, Dr. Pieter Cullis, has received another honour in recognition of his pioneering work on the development of LNP delivery systems.
Arpan Desai @ LNP Development Europe Summit
Arpan Desai, Managing Director of NTx's UK GENErator, will be speaking at Lipid Nanoparticles Development Europe Summit.
CSO Jayesh Kulkarni @ MilliporeSigma virtual mRNA Symposium
Hear our CSO Jayesh Kulkarni discuss the design of LNPs for extrahepatic gene therapy at this Oct 11 virtual mRNA Symposium organized by MilliporeSigma.
NanoVation Therapeutics™ & Baseimmune announce innovative mRNA vaccine collaboration
Baseimmune™ and NanoVation Therapeutics™ (NTx) today announced their preclinical partnership program to accelerate the development of more effective vaccines against a range of infectious diseases.
NTx scientists publish in European J. of Pharm. Sciences
The co-authors detail their efforts to broaden the application of LNPs in targeting non-hepatic tissues by developing LNP-based RNA therapies for the respiratory tract.
NTx’s Dr. Arpan Desai publishes in Journal of Controlled Release
NanoVation’s Dr. Arpan Desai (UK) and co-authors describe the systematic optimisation of lipid-peptide nanocomplexes for the delivery of mRNA in two murine cancer cell types...
NTx’s Drs. Jayesh Kulkarni & Pieter Cullis publish in Langmuir
Co-authored by NanoVation’s Drs Jayesh Kulkarni & Pieter Cullis, this article develops a straightforward “bottom-up” approach to manufacture drug-loaded LNP-GNP systems.
NTx’s Drs. Fariba Saadati & Marco Ciufolini publish in Chemistry: A European Journal
This paper describes a synthesis of ALC-0315 by a sequence that more than doubles the overall yield relative to the published one, and that employs much cleaner reactions...
NTx’s Dr. Jayesh Kulkarni publishes in Plant Cell on monolignol export by diffusion
NTx's Dr. Jayesh Kulkarni co-authored this article in The Plant Cell on monolignol export by diffusion down a polymerization-induced concentration gradient.
CEO Dominik Witzigmann Co-Organizes CRS Symposium on LNP-RNA Therapeutics
NanoVation Therapeutics™ CEO & Co-Founder Dr. Dominik Witzigmann co-organized a 2-day virtual symposium on “LNP-RNA Therapeutics: Beyond COVID.”
Co-Founder Dr. Pieter Cullis wins Gairdner Award
NanoVation™ Co-Founder Dr. Pieter Cullis and his colleagues Katalin Karikó and Drew Weissman were awarded the Gairdner International Award “for their pioneering work developing nucleoside-modified mRNA and LNP drug delivery..."
NTx UK’s Dr. Arpan Desai publishes in SLAS Discovery
Dr. Arpan Desai co-authored this article on arrayed CRISPR screening to identify novel targets that enhance the productive delivery of mRNA by MC3-based LNPs.
NanoVation Therapeutics™ launches UK hub
NanoVation Therapeutics™ (NTx) is pleased to announce the expansion of its global gene therapy builder with the launch of its first GENErator™, NanoVationTx™ UK.
LNP Formulation & Process Development Summit
Come hear CSO Dr. Jayesh Kulkarni discuss the composition of LNPs with respect to their efficacy & function.
NTx scientists publish on using anionic LNPs to deliver mRNA in Advanced Materials
NTx's Drs. Frederick Campbell, Dominik Witzigmann and Pieter Cullis co-authored this article on anionic LNPs that preferentially deliver mRNA to the hepatic reticuloendothelial system.
NTx @ RNA Leaders World Congress 2022
NanoVation Therapeutics is both a sponsor and speaker at the RNA leaders world Congress happening March 16-17th 2022.
NTx @ OBIO 2022
Looking for for the next big hit to invest in in the biotech industry? Come listen to us pitch at the Ontario Bioscience Innovation Organization (OBIO) Investment Summit.
NTx’s Dr. Arpan Desai publishes in Nanoscale on developing a high-throughput LNP screening platform
NTx UK's Dr. Arpan Desai co-authored this artilce on developing a high-throughput platform for screening LNPs for mRNA delivery.
Dr. Arpan Desai publishes in SMALL on mechanistic studies of an automated LNP
Dr. Arpan Desai co-authored this artlce in SMALL on how mechanistic studies of an automated LNP revealed pharmaceutical properties associated with enhanced mRNA functional delivery.
NTx @ 9th mRNA Health Conference
NTx CEO Dr. Witzigmann presents in-person at the 9th International mRNA Health Conference in Berlin, Germany
NTx CEO Dr. Witzigmann gives invited talk at 3rd CRIG Industrial Partnering Event
NTx CEO Dr. Witzigmann delivered an invited talk during “Bringing drug delivery to the market” session of the 3rd CRIG Industrial Partnering Event.
NTx CEO Dr. Witzigmann presents @ International Symposium on Phospholipids
NTx CEO Dr. Witzigmann spoke at the International Symposium on Phospholipids in Pharmaceutical Research 2021.
NTx scientists publish in American J. of Physiol.
NTx's Drs. Anthony Tam, Jayesh Kulkarni, Dominik Witzigmann and Pieter R Cullis co-authored this paper on FAM13A as potential therapeutic target in modulating airway tissue remodeling in COPD.
CIHR highlights role of LNPs in COVID vaccines
The Canadian Institutes of Health Research (CIHR) has highlighted the role of NTx's Dr. Pieter Cullis in developing the LNPs that have enabled mRNA vaccine development.
NTx Co-Founder Dr. Pieter Cullis interviewed on CBC
Listen to Dr. Pieter R Cullis on CBC radio's Quirks & Quarks, discussing the role of his work in the COVID 19 vaccines.
NTx Workshop @ CRS 2021
NanoVation co-organizes an Industry Educational Workshop as part of the Controlled Release Society Annual Meeting.
NTx’s Dr. Jayesh Kulkarni publishes on scalable production of LNPs containing Amphotericin B
Dr. Jayesh Kulkarni co-authored this paper in Langmuir on the scalable production of LNPs containing Amphotericin B.
NTx Co-Founders publish on current landscape of nucleic acid therapeutics
Three NTx co-founders wrote this review article in Nature Nanotechnology on the current landscape of nucleic acid therapeutics.
NTx scientists publish in SMALL on optimized LNPs for red light-triggered drug release
NTx's Drs Dominik Witzigmann and Pieter R Cullis published this article in Small, on optimized photoactivatable LNPs to enable red light-triggered drug release.
Media Contact
Marion Athané
Manager, Marketing and Communications